4/A: PLUS THERAPEUTICS CFO Amends RSU Vesting Details

PLUS THERAPEUTICS CFO Andrew Sims filed an amended Form 4 to correct the vesting schedule for 459,878 Restricted Stock Units.

Summary

• Andrew John Hugh MacIntyre Sims, Chief Financial Officer of PLUS THERAPEUTICS, INC. (PSTV), filed an amended Statement of Changes in Beneficial Ownership (Form 4/A).
• The amendment corrects the vesting terms for 459,878 Restricted Stock Units (RSUs) that were awarded on August 13, 2025.
• The RSUs will now vest over twelve quarters, in substantially equal 1/12th increments, beginning with the quarter ended September 30, 2025.
• The RSUs convert into shares of Common Stock on a one-for-one basis upon vesting.
• The filing also reports 1,379,636 stock options with an exercise price of $0.5744, granted on August 13, 2025, which vest over four years in equal 1/48th monthly increments and expire on August 12, 2035.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive due to the disclosure of executive equity compensation, which aligns management incentives with shareholder interests. The need for an amendment represents a minor administrative negative, but the correction itself is a positive for transparency.

Positives

• The grant of stock options and Restricted Stock Units aligns the Chief Financial Officer's interests with those of shareholders, providing an incentive for long-term performance.
• The company is ensuring accurate disclosure of executive compensation terms through this amendment.

Negatives

• An initial error in reporting the vesting terms of the Restricted Stock Units necessitated an amendment, indicating a minor administrative oversight.

Future Outlook

The filing details future vesting schedules for executive equity compensation, indicating a long-term incentive structure for the Chief Financial Officer.

Industry Context

This filing is a routine disclosure of executive compensation and beneficial ownership, common across all publicly traded companies, and does not directly relate to broader industry trends or competitive positioning.

Corporate Governance

Stakeholder Impact

• Shareholders: Benefit from accurate and transparent disclosure of executive compensation, which helps in evaluating management incentives and alignment with company performance.
• Management (Andrew Sims): The equity grants provide a long-term incentive, aligning personal financial interests with the company's success.

Next Steps

• The Restricted Stock Units will begin vesting in substantially equal 1/12th increments starting with the quarter ended September 30, 2025.
• The stock options will continue to vest over four years in equal 1/48th monthly increments from the issuance date of August 13, 2025.

Key Dates

Keywords

PLUS THERAPEUTICS, PSTV, Andrew Sims, CFO, Form 4/A, SEC filing, Restricted Stock Units, RSUs, Stock Options, Executive Compensation, Insider Trading, Vesting Schedule